Year: 2020

Euronet Worldwide, Inc., Acquires Bank of Ireland’s non-branch ATM fleet

Written by Customer Service on December 23, 2020. Posted in Mergers And Acquisitions.

LEAWOOD, Kan., Dec. 23, 2020 (GLOBE NEWSWIRE) — Euronet Worldwide, Inc. (NASDAQ: EEFT), a leading global electronic payments provider, has announced the acquisition of Bank of Ireland’s entire fleet of non-branch ATMs in the Republic of Ireland. Under terms of the agreement, Euronet will acquire 700 non-branch ATMs while the bank will still own and operate more than 750 ATMs located across its extensive branch network. The transfer of ownership to Euronet is planned for Feb 28, 2021. Euronet will assume full responsibility for managing the acquired ATM network and integrating it with the company’s existing ATM estate in the Republic of Ireland. In addition, Euronet plans additional investments to upgrade and enhance the ATMs with modern technology and new functionality to the benefit of consumers.No disruption in the operation...

Kvanto förvärvar 51 % av Mobileware Technology för att kombinera och utvidga sin digitala betalningsverksamhet i Indien

Written by Customer Service on December 23, 2020. Posted in Mergers And Acquisitions.

KÖPENHAMN, Danmark, Dec. 23, 2020 (GLOBE NEWSWIRE) — Kvanto Payment Services A/S (”Kvanto”) är glada över att tillkännage undertecknandet av ett avtal (”Avtalet”) med Mobileware Technology Pvt. Ltd. (”MWT”). Enligt villkoren i avtalet kommer Kvanto att äga 51 % av MWT i Indien för att fortsätta implementera Kvantos betalningsplattform i kombination med MWT:s befintliga betalningsteknik och kundbas. MWT kommer att representera och driva Kvanto framåt genom den exponentiellt växande marknaden för digital betalningshantering i Indien.Mobileware har implementerat digitala bankprodukter på ledande banker i Indien, inklusive Yes Bank och Kotak Mahindra Bank. Satsningen är baserad på Kvantos framgång med sin beprövade toppmoderna plattform och täckning som når över 400 banker över hela världen, och Mobilewares långvariga affärsrelationer...

Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update

Written by Customer Service on December 23, 2020. Posted in Earnings Releases And Operating Results.

All planned clinical trials for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) wet AMD BLA now fully enrolled or completedPivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration trial for ONS-5010 (NORSE TWO) with new BLA filing expected in second half of 2021MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020.Outlook Therapeutics also provided a clinical development and pre-commercialization update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab-vikg...

Acceptance and sale of FSRU LNG Croatia

Written by Customer Service on December 23, 2020. Posted in Public Companies.

Golar LNG Limited (“Golar”) announces today that the FSRU LNG Croatia (formerly known as the Golar Viking) has been accepted by its customer LNG Hrvatska d.o.o. (“LNG Hrvatska”), and that the sale of the FSRU has been completed. The sale will release approximately $47 million of free cash to Golar between Q4 2020 and Q1 2021 after repayment of the vessel debt facility and settlement of remaining conversion and commissioning costs. Golar will now operate and maintain the LNG Croatia for a minimum period of 10 years under contract to LNG Hrvatska.Forward-Looking StatementsThis press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended) which reflects management’s current expectations, estimates and projections about its operations. All statements, other than statements...

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Written by Customer Service on December 23, 2020. Posted in Public Companies.

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.The Company’s clinical safety team has actively monitored the ongoing interim data of...

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

Written by Customer Service on December 23, 2020. Posted in Public Companies.

FLORHAM PARK, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of its previously announced underwritten public offering of its common stock for gross proceeds of approximately $24.5 million at a public offering price of $1.35 per share of common stock, prior to deducting underwriting discounts and commissions and estimated offering expenses.The shares of common stock in the public offering were offered pursuant to a registration statement on Form S-3 (File No. 333-244362), which was declared effective by the Securities and Exchange Commission (SEC) on August 20, 2020. The public offering was made only by means of a written prospectus...

MindBeacon Holdings Inc. Completes Initial Public Offering

Written by Customer Service on December 23, 2020. Posted in Public Companies.

Not for distribution to U.S. news wire services or dissemination in the United StatesTORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — MindBeacon Holdings Inc. (“MindBeacon” or the “Company”) (TSX: MBCN) announced today the successful closing of its previously announced initial public offering (the “Offering”) pursuant to which it and TELUS Corporation, 1930339 Ontario Inc., 2451585 Ontario Inc. and 1964998 Ontario Inc. (the “Selling Shareholders”) sold an aggregate of 9,343,750 common shares at a price of $8.00 per share, for total gross proceeds of $74,750,000. The Offering includes the exercise in full by the Underwriters (as defined below) of their over-allotment option to acquire 1,218,750 additional shares of the Company from the Selling Shareholders. The Company received gross proceeds of $65,000,000 and the Selling Shareholders...

MindBeacon Holdings Inc. réalise un premier appel public à l’épargne

Written by Customer Service on December 23, 2020. Posted in Public Companies.

Ne pas distribuer aux agences de presse américaines ni diffuser aux États-UnisTORONTO, 23 déc. 2020 (GLOBE NEWSWIRE) — MindBeacon Holdings Inc. (« MindBeacon » ou la « Société ») (TSX : MBCN) a annoncé aujourd’hui la clôture réussie de son premier appel public à l’épargne (le « placement ») précédemment annoncé, dans le cadre duquel MindBeacon et TELUS Corporation, 1930339 Ontario Inc., 2451585 Ontario Inc. et 1964998 Ontario Inc. (les « actionnaires vendeurs ») ont vendu un total de 9 343 750 actions ordinaires au prix de 8,00 $ par action, pour un produit brut total de 74 750 000 $. Le placement comprend l’exercice intégral par les preneurs fermes (terme défini ci-dessous) de leur option de surallocation leur permettant d’acquérir 1 218 750 actions supplémentaires de la Société auprès des actionnaires vendeurs. La Société a reçu...

Gritstone Oncology Announces $110 Million Private Placement

Written by Customer Service on December 23, 2020. Posted in Public Companies.

EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) — Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that it has executed a securities purchase agreement to raise gross proceeds of $110 million resulting from the sale of shares of its common stock and/or pre-funded warrants through a private investment in public equity (PIPE) financing at a price per share of $3.34. The financing was led by certain existing and new investors, Redmile Group, Avidity Partners and EcoR1 Capital.The PIPE financing is subject to customary closing conditions and is expected to close on December 28, 2020. The PIPE financing was done in compliance with applicable Nasdaq rules and priced at the “Minimum Price” (as defined...

Signature Resources Announces Nordmin Engagement

Written by Customer Service on December 23, 2020. Posted in Public Companies.

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) — Signature Resources Ltd. (TSXV: SGU, OTCQB: SGGTF, FSE 3S3) (“Signature” or the “Company”) is pleased to announce the engagement of Nordmin Engineering Ltd. (“Nordmin”) to provide technical services.Stock OptionsThe Company has also granted 2,575,000 incentive stock options to directors, officers and consultants of the Company. 2,500,000 options shall have an exercise price of $0.13, expire five years from the date of issuance, and shall vest 25% immediately, and 12.5% ever six months thereafter through to the third anniversary. The other 75,000 stock options shall have an exercise price of $0.13, expire one year from the date of issuance and shall vest immediately upon issuance.About SignatureThe Lingman Lake gold property consists of 622 staked claims, four free...

Year: 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals